ABEO - アビオナ・セラピュ―ティクス （Abeona Therapeutics Inc.） アビオナ・セラピュ―ティクスABEOのチャート
ABEOの企業情報
| symbol | ABEO |
|---|---|
| 会社名 | Abeona Therapeutics Inc （アビオナ・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アベオナ・セラピューティクス(Abeona Therapeutics Inc.)は希少遺伝性疾患の新規遺伝子治療法を開発する臨床段階のバイオ医薬品会社である。同社の主導プログラムには、劣性栄養障害性表皮水疱症(RDEB)向けの遺伝子矯正皮膚移植片EB-101及びサンフィリッポ症候群A型（MPS IIIA）向けのアデノ随伴ウイルス(AAV)ベース遺伝子療法であるABO-102（AAV-SGSH）を含む。同社はまた、サンフリッポ症候群B型（MPS IIIB）向けのABO-101（AAV-NAGLU）、若年型バツテン疾患（JNCL）向けのABO-201(AAV-CLN3)、幼児型バツテン疾患(INCL)の治療向けのABO-202 (AAV-CLN1)、表皮水疱症向けのEB-201、ファンコーニ貧血障害向けのABO-301 (AAV-FANCC)、並びに希少血液疾患向けの遺伝子療法である新規クリスパー・キャス9(CRISPR/Cas9)ベースの遺伝子編集療法を使用するABO-302を開発する。同社はまた、独自のSalt Diafiltrationエタノールフリープロセスを使用して、遺伝性慢性閉塞性肺疾患(COPD)向けのアルファ-1プロテアーゼ阻害剤（SDF Alpha）を含む血漿ベースのタンパク質療法パイプラインを所有する。 アビオナ・セラピュ―ティクスは米国のバイオ医薬品メ―カ―。遺伝子治療や希少疾患のためのプラズマベ―スの製品の開発に焦点を当てる。主要プログラムとして、遺伝性ムコ多糖代謝異常のサンフィリポ症候群(MPS IIIA及びIIIB)を研究。同社の主な市販段階の製品には「MuGard」と「ProctiGard」がある。本社はテキサス州ダラス。 Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona's clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in Phase 3 development, as well as ABO-102 and ABO-101, novel AAV-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively, in Phase 1/2 development. The Company's portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical needs. Abeona's novel, next-generation AIM™ capsids have shown potential to improve tropism profiles for a variety of devastating diseases. Abeona's fully functional, gene and cell therapy GMP manufacturing facility produces EB-101 for the pivotal Phase 3 VIITAL™ study and is capable of clinical and commercial production of AAV-based gene therapies. |
| 本社所在地 | 1330 Avenue of the Americas 33rd Floor New York NY 10019 USA |
| 代表者氏名 | Steven H. Rouhandeh スティーブンH.ローランハンド |
| 代表者役職名 | Executive Chairman of the Board 取締役会長 |
| 電話番号 | +1 214-905-5100 |
| 設立年月日 | 27181 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 42人 |
| url | www.abeonatherapeutics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/abeo |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -33.99400 |
| 終値（lastsale） | 11.13 |
| 時価総額（marketcap） | 533608762.05 |
| 時価総額 | 時価総額（百万ドル） 516.34920 |
| 売上高 | 売上高（百万ドル） 3.85100 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 396.50720 |
| 当期純利益 | 当期純利益（百万ドル） -33.95600 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Abeona Therapeutics Inc revenues increased from $403K to $3.4M. Net loss increased 49% to $20.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects R&D exp increase from $1.8M to $14.1M (expense) Selling/General/Admin. Expense increase from $1.5M to $4.9M (expense). |
ABEOのテクニカル分析
ABEOのニュース
Abeona Therapeutics GAAP EPS of -$5.53 misses by $1.61, revenue of $1.41M misses by $0.91M 2023/03/29 12:10:01 Seeking Alpha
Abeona Therapeutics press release (ABEO): FY GAAP EPS of -$5.53 misses by $1.61.Revenue of $1.41M (-53.0% Y/Y) misses by $0.91M.Cash, cash equivalents, restricted cash and…
Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update 2023/03/29 11:30:00 GlobeNewswire
Expects to submit BLA for EB-101 to FDA in late-2Q/early-3Q 2023 based on positive Phase 3 VIITAL™ study results announced in 4Q 2022
Abeona Therapeutics Announces New Employee Inducement 2023/03/25 04:25:07 Medium
Continue reading on Medium »
Abeona Therapeutics Announces New Employee Inducement Grants 2023/03/24 11:30:00 Wallstreet:Online
NEW YORK and CLEVELAND, March 24, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new employees who joined Abeona. On March 23, 2023, Abeona granted restricted stock equity awards to six employees as an inducement for them to accept employment, which equity awards relate to, in the aggregate, up to 131,750 restricted shares of Abeona
Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting 2023/03/16 11:30:00 Wallstreet:Online
NEW YORK and CLEVELAND, March 16, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that additional data from its pivotal Phase 3 VIITAL study of EB-101 for recessive dystrophic epidermolysis bullosa (RDEB) has been accepted for an oral presentation at the inaugural International Societies for Investigative Dermatology (ISID) Meeting, being held May 10-13, 2023 in
ABEO, RLX and SSTI among mid-day movers 2022/10/12 16:47:39 Seeking Alpha
Gianers: Hempacco Co HPCO +36%.Happiness Development Group (HAPP) +33%.Applied DNA Sciences APDN +29%.Pineapple Energy PEGY +26%.Gatos Silver GATO +24%.Greenwave Technology Solutions…
Chronic Wounds Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies - Abeona Therapeutics, PolarityTE, and others 2022/10/11 10:04:35 OpenPR
The Chronic Wounds market is expected to surge due to the disease''s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Wounds pipeline products will significantly revolutionize the Chronic Wounds market dynamics. DelveInsight''s "Chronic Wounds
Why NVIDIA, Microsoft And Amazon Shares Traded Lower; Here Are 73 Biggest Movers From Friday 2022/10/10 09:28:51 Benzinga
Gainers Innovative Eyewear, Inc. (NASDAQ: LUCY ) climbed 61.4% to close at $2.63 on abnormally-high volume. The company released its October investor presentation yesterday. Inventiva S.A. (NASDAQ: IVA ) climbed 69.5% to settle at $7.05 after gaining around 10% on Thursday. Minim, Inc. (NASDAQ: MINM ) rose 50.9% to close at $0.32 on Friday. Minim, during August, posted a Q2 loss of $0.10 per share. New Concept Energy, Inc. (NYSE: GBR ) gained 30% to close at $1.56. Abeona Therapeutics Inc. (NASDAQ: ABEO ) climbed 25.3% to close at $4.41. Abeona Therapeutics recently announced completion of patient follow-up in pivotal Phase 3 VIITAL study of EB-101. Aehr Test Systems (NASDAQ: AEHR ) climbed 23.9% to close at $17.19 after the company announced better-than-expected Q1 EPS and sales results and issued guidance. Brookdale Senior Living Inc. (NYSE: BKD ) gained 20% to close at $4.81. Brookdale Senior Living is said to explore a sale, Bloomberg reported. Ambac Financial Group, Inc (NASDAQ: AMBC ) climbed 15.6% to close at $14.80 after the company announced it settled its RMBS litigations against Bank of America for $1.84 billion. eMagin Corporation (NYSE: EMAN ) rose 15.6% to close at $0.7170. eMagin, in August, reported second-quarter FY22 revenue growth of 14% year-on-year to $7.2 million.
CGC, ABEO and NVIV among premarket gainers 2022/10/07 17:18:33 Seeking Alpha
Gainers: Innovative Eyewear LUCY +98%.Green Giant (GGE) +34%.Top Ships TOPS +29%.Inventiva S.A
Do investors need to be concerned about Abeona Therapeutics Inc. (ABEO)? 2022/10/06 13:08:00 US Post News
A share of Abeona Therapeutics Inc. (NASDAQ:ABEO) closed at $3.21 per share on Wednesday, down from $3.41 day before. While Abeona Therapeutics Inc. has underperformed by -5.87%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ABEO fell by -86.49%, with highs and lows ranging from $26.75 […]
Abeona Therapeutics Inc. (ABEO) Gain 0.60%, Marking Win By Bears 2022/06/29 13:30:00 Marketing Sentinel
Abeona Therapeutics Inc. (NASDAQ:ABEO) has a beta value of 1.33 and has seen 2.81 million shares traded in the last trading session. The company, currently valued at $29.69M, closed the last trade at $0.18 per share which meant it lost $0.0 on the day or 0.60% during that session. The ABEO stock price is -866.67% … Abeona Therapeutics Inc. (ABEO) Gain 0.60%, Marking Win By Bears Read More »
Abeona Therapeutics Inc. (NASDAQ: ABEO) Surged 19.30% In 6 Months – Here’s What To Expect Next 2022/06/24 11:30:00 Marketing Sentinel
During the last session, Abeona Therapeutics Inc. (NASDAQ:ABEO)’s traded shares were 2.57 million, with the beta value of the company hitting 1.39. At the end of the trading day, the stock’s price was $0.19, reflecting an intraday gain of 8.11% or $0.02. The 52-week high for the ABEO share is $1.75, that puts it down … Abeona Therapeutics Inc. (NASDAQ: ABEO) Surged 19.30% In 6 Months – Here’s What To Expect Next Read More »
Abeona Therapeutics Inc. (NASDAQ: ABEO) Has Decreased By -90.87 Percent This Year. Is It A Better Buy Than Others? 2022/06/17 14:00:00 Marketing Sentinel
Abeona Therapeutics Inc. (NASDAQ:ABEO)’s traded shares stood at 1.08 million during the last session, with the company’s beta value hitting 1.48. At the close of trading, the stock’s price was $0.16, to imply a decrease of -3.40% or $0.0 in intraday trading. The ABEO share’s 52-week high remains $1.77, putting it -1006.25% down since that … Abeona Therapeutics Inc. (NASDAQ: ABEO) Has Decreased By -90.87 Percent This Year. Is It A Better Buy Than Others? Read More »